Founder, Infinitus, notes the the emerging themes at Access USA 2026, including regulatory shifts, the collapse of the traditional hub model, and the proliferation of fragmented AI point solutions. In ...

In today's Pharmaceutical Executive Daily, Novartis agrees to acquire a pan-mutant-selective inhibitor from Synnovation Therapeutics in a deal worth up to $3 billion while Collegium moves to acquire ...

FDA authorization of semaglutide 7.2 mg once weekly was supported by two 72-week Phase III programs and reviewed under the Commissioner’s National Priority Voucher, shortening standard timelines. STEP ...

This episode of The Ron Lanton Report examines how the relationship between policy and market behavior has fundamentally shifted. Regulatory signals are now moving valuations and shaping strategic ...

Nishith Rastogi is the CEO and co-founder of Locus, where he leads global strategy, innovation, and product development. He drives the company’s international expansion and oversees its technology ...

Founder, Infinitus, notes the the emerging themes at Access USA 2026, including regulatory shifts, the collapse of the traditional hub model, and the proliferation of fragmented AI point solutions.

Launched in January, TrumpRx.gov is part of a series of most-favored-nation deals struck between the Trump administration and ...

Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.

Matt Turner, President of Patient Affordability, Paysign discusses the evolving financial threats to pharmaceutical ...

One key failure mechanism is the logistic implementation for the DCT trials. A lot of times, when you go to a global trial, there's a lot of logistic management for DCT. Let's say you must ship the ...

Nominate a colleague with impressive leadership and career intentions – even yourself! – for the Pharmaceutical Executive ...

Matthew Turner, President of Patient Affordability, Paysign, touches on how evolving payer tactics appear to be pushing ...